Canaccord Genuity Rates Definium Therapeutics (DFTX) buy

Analyst Sumant Kulkarni at Canaccord Genuity maintains a buy rating with a $38 price target for Definium Therapeutics, a 3.63% upside from the current price.

By EarningsIQ Research Desk · Published Jun 16, 2026, 12:01 PM EDT · Updated Jun 23, 2026, 9:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Canaccord Genuity rated Definium Therapeutics, Inc. ($DFTX) "buy" with a $38 price target on June 16, 2026.

Since the rating, $DFTX is up 49.8% after 1 week, up 82.5% after 1 month and up 32.9% to date (from the $24.16 close on Jun 16, 2026).

DFTX Definium Therapeutics, Inc.

$32.10 +135.34% year to date

Daily close · Oct 16, 2026

Key Points

Canaccord Genuity reiterated its buy rating on Definium Therapeutics, Inc. (DFTX) with a $38 price target on June 16, 2026.
Canaccord Genuity's $38 price target implies 3.63% upside from Definium Therapeutics, Inc.'s ($DFTX) current $36.67 share price.
Definium Therapeutics trades at $23.77 with a market cap of $2.59 billion; the company is not yet profitable, impacting its P/E ratio.
Insider buying activity was reported on June 11, 2026, and analysts have consistently set buy ratings with targets up to $70.

Get $DFTX trade alerts by text

We text you when insiders, Congress or big funds trade $DFTX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Definium Therapeutics, Inc. alert may contain errors. Disclosures

Analyst Sumant Kulkarni from Canaccord Genuity reiterated a buy rating for Definium Therapeutics, Inc. (NasdaqGS:DFTX) on June 16, 2026. The firm set a price target of $38, suggesting confidence in the company's future prospects.

Other Institutional Activity in Definium Therapeutics

BlackRock, Inc. grew its holdings to 8,480,230 shares, valued at approximately $160.3 million. Driehaus Capital Management LLC reduced its position by 625,313 shares, leaving it with 5,911,889 shares worth about $111.7 million. Avoro Capital Advisors LLC added 5,000,000 shares, bringing its total to 5,000,000 shares valued at $94.5 million. Janus Henderson Group PLC and Deep Track Capital, LP both increased their stakes, holding 3,556,041 and 3,000,000 shares, valued at $67.2 million and $56.7 million, respectively.

Definium Therapeutics, Inc. Stock Down 5.5%

Shares of DFTX are trading near $23.77. The company, with a market cap of $2.59 billion, does not yet have a meaningful P/E ratio as it is unprofitable. It has a beta of 2.378, indicating higher volatility. The stock's 52-week range is between $6.35 and $26.25, with 50-day and 200-day moving averages of $22.39 and $16.06, respectively. Definium's current ratio is strong at 4.69, with a quick ratio of 4.60 and a debt-to-equity ratio of 14.62.

12-month forecast

$DFTX price target

Definium Therapeutics, Inc. daily closes and this analyst's $38 target. Not advice.

Insider Buying and Selling at Definium Therapeutics, Inc.

Several insiders made purchases on June 11, 2026. Andreas Krebs bought 19,188 shares, while Roger Crystal also acquired 19,188 shares. Suzanne Louise Bruhn, Carol Vallone, David Gryska, and Roger Adsett purchased 4,666, 4,666, 4,666, and 3,555 shares, respectively. These transactions were not conducted under a 10b5-1 plan.

Analysts Set New Price Targets

On June 16, 2026, Canaccord Genuity maintained its buy rating with a $38 price target. Piper Sandler also maintained a buy rating on May 8, 2026, with a target of $48. Leerink Partners and Stifel both have buy ratings with $30 targets set in April 2026. The consensus among 15 analysts is a strong buy, with an average target price of $39.87.

About Definium Therapeutics

Definium Therapeutics, Inc. is a biopharmaceutical company based in New York, NY. It focuses on developing treatments for brain health disorders. The company's leading products include DT120, in phase 3 trials for anxiety and depression, and DT402, in phase 2a trials for autism spectrum disorders. Led by CEO Robert Barrow, Definium has 105 employees.

Bottom Line

Definium Therapeutics is attracting attention from analysts with its promising pipeline in brain health treatments. The reiterated buy rating from Canaccord Genuity underscores continued confidence. Investors should note that 13F filings are backward-looking and may not reflect current positions.